MRG-001

DRUG4 trials

Sponsors

MedRegen LLC

Conditions

ARDS, HumanAbdominal WoundAcute Alcoholic HepatitisAlcoholic HepatitisAmyotrophic Lateral SclerosisCOVID-19Lou Gehrig DiseaseMotor Neuron Atrophy

Phase 2

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

MedRegen LLCARDS, Human, COVID-19, Regeneration +1

Start: 2021-12-01End: 2022-07-01Target: 40Updated: 2022-02-15

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

CompletedNCT05844527

MedRegen LLCAbdominal Wound, Wound of Skin

Start: 2023-11-20End: 2024-09-01Updated: 2025-09-08

MRG-001 in Patients With Alcoholic Hepatitis

Not yet recruitingNCT06307522

MedRegen LLCAcute Alcoholic Hepatitis, Alcoholic Hepatitis

Start: 2024-09-01End: 2026-12-01Target: 32Updated: 2024-03-13

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Not yet recruitingNCT06315608

MedRegen LLCAmyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Atrophy +1

Start: 2025-07-01End: 2026-03-01Target: 10Updated: 2024-08-23

Related Papers

A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects

Cell Reports Medicine2023-08-256 citations